Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - aġenti għad-dermatite, esklużi kortikosterojdi - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psorajiżi - immunosoppressanti - treatment of moderate-to-severe plaque psoriasis in adults.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare b.v. - maraviroc - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only ccr5-tropic hiv-1 detectable,.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine, zidovudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - epivir huwa indikat bħala parti mit-terapija kombinata antiretrovirali għat-trattament ta 'adulti u tfal infettati bil-virus ta' l-immunodefiċjenza umana (hiv).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare bv - dolutegravir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare bv - fosamprenavir kalċju - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - telzir fil kombinazzjoni b ' doża baxxa ritonavir huwa indikat għat-trattament ta ' human-immunodeficiency-virus-type-1-infected adulti, adolixxenti u tfal ta ' sitt snin u hawn fuq flimkien mal-prodotti mediċinali l-oħra antiretroviral. fl-moderatament antiretrovirali adulti esperjenzati, telzir flimkien ma 'doża baxxa ta' ritonavir ma weriex l-istess effikaċja ta ' lopinavir / ritonavir. l-ebda sarux studji komparattivi fi tfal jew l-adoloxxenti. fil-pazjenti li ħadu trattament qawwi qabel, l-użu ta 'telzir flimkien ma' doża baxxa ta ' ritonavir ma ġiex studjat biżżejjed. fl-inibituri tal-inibitur tal-pazjenti b'esperjenza, l-għażla ta ' telzir għandha tkun ibbażata fuq testijiet tar-reżistenza virali u l-istorja tat-trattament.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir tas-sodju, rilpivirina hydrochloride - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - juluca huwa indikat għall-kura tal-vajrus tal-immunodefiċjenza umana tat-tip 1 (hiv-1) f'adulti li huma viroloġikament-mrażżna (hiv-1 rna.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir tas-sodju, lamivudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - dovato huwa indikat għall-kura tal-vajrus tal-immunodefiċjenza umana tat-tip 1 (hiv-1) f'adulti u adolexxenti'il fuq minn 12-il sena li jiżnu mill-inqas 40 kg, bl-ebda magħrufa jew suspettati reżistenza biex l - ' integrase inibitur tal-klassi, jew lamivudine.